This strategy was further developed into a clinical nano-therapy treatment, SGT-53, that is currently in advanced clinical trial stage for various solid cancers and even for COVID-19, in which p53 is thought to play a role in viral infection [142,143,144]. This evidence concerns the gene TP53 and viral infectious disease.